Literature DB >> 17876377

Left atrial enlargement as a predictor of recurrences in lone paroxysmal atrial fibrillation.

Valerio Zacà1, Maurizio Galderisi, Sergio Mondillo, Marta Focardi, Piercarlo Ballo, Francesco Guerrini.   

Abstract

BACKGROUND: A mild increase in left atrial (LA) size predicts arrhythmia onset and adverse events in patients with lone paroxysmal atrial fibrillation (LPAF). However, the role of LA size as a predictor of LPAF recurrences is still controversial.
OBJECTIVE: The potential role of LA size in affecting the frequency of recurrent episodes in patients with LPAF was investigated.
METHODS: Fifty-one patients who were admitted for a first episode of LPAF and presenting with one recurrence (group A, n=20), two or three recurrences (group B, n=18), or four or more recurrences (group C, n=13) during an average follow-up period of two years were retrospectively selected. The M-mode LA anteroposterior diameter (LAAPd) was used as an echocardiographic surrogate of LA size.
RESULTS: At baseline, LA size was normal or borderline in the control group, group A and group B, but significantly increased in group C. At two years' follow-up, a significant further LA enlargement from baseline was observed in group B (LAAPd 40+/-1.1 mm versus 40.7+/-1.2 mm, P<0.01) and in group C (LAAPd 41.4+/-1.6 mm versus 42.7+/-1.7 mm, P<0.001), while LA size remained substantially unchanged in the control group and in group A.
CONCLUSIONS: Observations confirmed the association of increased LA size and LPAF onset, and provide the first evidence for a potential role of LA progressive enlargement as a predictor of arrhythmic recurrences.

Entities:  

Mesh:

Year:  2007        PMID: 17876377      PMCID: PMC2651363          DOI: 10.1016/s0828-282x(07)70841-3

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  27 in total

1.  Acute treatment of atrial fibrillation: spontaneous conversion rates and cost of care.

Authors:  J T Dell'Orfano; H Patel; D L Wolbrette; J C Luck; G V Naccarelli
Journal:  Am J Cardiol       Date:  1999-03-01       Impact factor: 2.778

2.  ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; G Gregoratos; L F Hiratzka; A K Jacobs; R O Russell; S C Smith; W W Klein; A Alonso-Garcia; C Blomström-Lundqvist; G de Backer; M Flather; J Hradec; A Oto; A Parkhomenko; S Silber; A Torbicki
Journal:  Circulation       Date:  2001-10-23       Impact factor: 29.690

3.  How should left atrial size be reported? Comparative assessment with use of multiple echocardiographic methods.

Authors:  Banthit Khankirawatana; Suwanee Khankirawatana; Thomas Porter
Journal:  Am Heart J       Date:  2004-02       Impact factor: 4.749

Review 4.  Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy.

Authors:  G V Naccarelli; J T Dell'Orfano; D L Wolbrette; H M Patel; J C Luck
Journal:  Am J Cardiol       Date:  2000-05-25       Impact factor: 2.778

5.  [Atrial stunning and pharmacologic cardioversion in idiopathic atrial fibrillation of recent onset].

Authors:  S Paventi; M A Parafati; C A Pellegrino; U Bevilacqua; A Paggi
Journal:  Minerva Cardioangiol       Date:  1999 Jul-Aug       Impact factor: 1.347

Review 6.  Epidemiology and natural history of atrial fibrillation: clinical implications.

Authors:  S S Chugh; J L Blackshear; W K Shen; S C Hammill; B J Gersh
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

7.  Relationship between atrial tachyarrhythmias and symptoms.

Authors:  S Adam Strickberger; John Ip; Sanjeev Saksena; Ken Curry; Tristram D Bahnson; Paul D Ziegler
Journal:  Heart Rhythm       Date:  2005-02       Impact factor: 6.343

8.  Serial evaluation of left atrial dimension after cardioversion for atrial fibrillation and relation to atrial function.

Authors:  A V Mattioli; S Sansoni; G R Lucchi; G Mattioli
Journal:  Am J Cardiol       Date:  2000-04-01       Impact factor: 2.778

Review 9.  Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter.

Authors:  Ijaz A Khan
Journal:  Am Heart J       Date:  2002-07       Impact factor: 4.749

10.  Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care.

Authors:  Carsten W Israel; Gerian Grönefeld; Joachim R Ehrlich; Yi-Gang Li; Stefan H Hohnloser
Journal:  J Am Coll Cardiol       Date:  2004-01-07       Impact factor: 24.094

View more
  3 in total

Review 1.  Can echocardiography improve the prediction of thromboembolic risk in atrial fibrillation? Evidences and perspectives.

Authors:  Antonella Tufano; Maurizio Galderisi
Journal:  Intern Emerg Med       Date:  2020-03-02       Impact factor: 3.397

2.  Clinically unrecognized mitral regurgitation is prevalent in lone atrial fibrillation.

Authors:  Sanjiv Sharma; Joel Lardizabal; Mark Monterroso; Neil Bhambi; Rohan Sharma; Rasham Sandhu; Sarabjeet Singh
Journal:  World J Cardiol       Date:  2012-05-26

3.  Anatomical characteristics of pulmonary veins for the prediction of postoperative recurrence after radiofrequency catheter ablation of atrial fibrillation.

Authors:  Wei Wei; Jun-Bo Ge; Yu Zou; Li Lin; Ying Cai; Xue-Bo Liu; Wen-Qing Zhu
Journal:  PLoS One       Date:  2014-04-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.